Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29796572 | 1.00 | TGFBR1 (0.43) | TGFBR1MTORCYP2D6TGFBR2MAP3K20 | |
| SCHEMBL23408107 | 0.86 | TGFBR1 (0.43) | TGFBR1MTORCYP2D6TGFBR2MAP3K20 | |
| SCHEMBL29796536 | 0.84 | TGFBR1 (0.43) | TGFBR1MTORCYP2D6TGFBR2MAP3K20 | |
| SCHEMBL23389618 | 0.84 | TGFBR1 (0.43) | TGFBR1MTORCYP2D6TGFBR2MAP3K20 | |
| SCHEMBL25822576 | 0.83 | TGFBR1 (0.43) | TGFBR1IDO1 | |
| SCHEMBL23389848 | 0.83 | TGFBR1 (0.45) | TGFBR1MTORMAPK14 | |
| SCHEMBL29796586 | 0.83 | TGFBR1 (0.45) | TGFBR1MTORMAPK14 | |
| SCHEMBL23389914 | 0.81 | TGFBR1 (0.42) | TGFBR1MTORCYP2D6TGFBR2MAP3K20 | |
| SCHEMBL29796624 | 0.81 | TGFBR1 (0.42) | TGFBR1MTORCYP2D6TGFBR2MAP3K20 | |
| SCHEMBL4068870 | 0.81 | TGFBR1 (0.61) | TGFBR1MTORMAPK14CCR1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| CN-114728941-A | Substituted 1, 5-naphthyridines or quinolines as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021102468-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| WO-2021102468-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | TGFBR1 211/4885MTOR 2401/4885CYP2D6 3809/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | TGFBR1 211/4885MTOR 2401/4885CYP2D6 3809/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | TGFBR1 211/4885MTOR 2401/4885CYP2D6 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.